All Publications


  • To Wait or Not to Wait? Covid-19 Vaccination Mitigates Adverse Surgical Outcomes. Annals of surgery Baiu, I., Hawn, M. 2022

    View details for DOI 10.1097/SLA.0000000000005675

    View details for PubMedID 35943196

  • Partial Tendon Injury at the Tendon-to-Bone Enthesis Activates Skeletal Stem Cells. Stem cells translational medicine Titan, A. L., Davitt, M., Foster, D., Salhotra, A., Menon, S., Chen, K., Fahy, E., Lopez, M., Jones, R. E., Baiu, I., Burcham, A., Januszyk, M., Gurtner, G., Fox, P., Chan, C., Quarto, N., Longaker, M. 2022

    Abstract

    The tendon enthesis plays a critical role in facilitating movement and reducing stress within joints. Partial enthesis injuries heal in a mechanically inferior manner and never achieve healthy tissue function. The cells responsible for tendon-to-bone healing remain incompletely characterized and their origin is unknown. Here, we evaluated the putative role of mouse skeletal stem cells (mSSCs) in the enthesis after partial-injury. We found that mSSCs were present at elevated levels within the enthesis following injury and that these cells downregulated TGFβ signaling pathway elements at both the RNA and protein levels. Exogenous application of TGFβ post-injury led to a reduced mSSC response and impaired healing, whereas treatment with a TGFβ inhibitor (SB43154) resulted in a more robust mSSC response. Collectively, these data suggest that mSSCs may augment tendon-to-bone healing by dampening the effects of TGFβ signaling within the mSSC niche.

    View details for DOI 10.1093/stcltm/szac027

    View details for PubMedID 35640155

  • Freezing the Future. Annals of surgery Baiu, I. 1800

    View details for DOI 10.1097/SLA.0000000000005397

    View details for PubMedID 35081571

  • A national analysis of open versus minimally invasive thymectomy for stage I-III thymic carcinoma. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery Hurd, J., Haridas, C., Potter, A., Baiu, I., Beqari, J., Deng, J., Liou, D., Patel, D., Yang, C. J. 2022

    Abstract

    The oncological efficacy of minimally invasive thymectomy for thymic carcinoma is not well characterized. We compared overall survival and short-term outcomes between open and minimally invasive surgical (video-assisted thoracoscopic and robotic) approaches using the National Cancer Database.Perioperative outcomes and overall survival of patients who underwent open versus minimally invasive thymectomy for Masaoka stage I-III thymic carcinoma from 2010 to 2015 in the National Cancer Database were evaluated using propensity score-matched analysis and multivariable Cox proportional hazards modelling. Outcomes by surgical approach were assessed using an intent-to-treat analysis.Of the 216 thymectomies that were evaluated, 43 (20%) were performed with minimally invasive techniques (22 video-assisted thoracoscopic and 21 robotic). The minimally invasive approach was associated with a shorter median length of stay when compared to the open approach (3 vs 5 days, P < 0.001). In the propensity score-matched analysis of 30 open and 30 minimally invasive thymectomies, the minimally invasive group did not differ significantly in median length of stay (3 vs 4.5 days, P = 0.27), 30-day readmission (P = 0.13), 30-day mortality (P = 0.60), 90-day mortality (P = 0.60), margin positivity (P = 0.39) and 5-year survival (78.6% vs 54.6%, P = 0.15) when compared to the open group.In this national analysis, minimally invasive thymectomy for stage I-III thymic carcinoma was found to have no significant differences in short-term outcomes and overall survival when compared to open thymectomy.

    View details for DOI 10.1093/ejcts/ezac159

    View details for PubMedID 35259241

  • Commentary: Inspiring a New Generation of Healthcare Workers. Seminars in thoracic and cardiovascular surgery Baiu, I., Lui, N. S. 2021

    View details for DOI 10.1053/j.semtcvs.2021.08.006

    View details for PubMedID 34407436

  • The role of gender in non-small cell lung cancer: a narrative review JOURNAL OF THORACIC DISEASE Baiu, I., Titan, A. L., Martin, L. W., Wolf, A., Backhus, L. 2021; 13 (6): 3816-3826
  • The role of gender in non-small cell lung cancer: a narrative review. Journal of thoracic disease Baiu, I., Titan, A. L., Martin, L. W., Wolf, A., Backhus, L. 2021; 13 (6): 3816-3826

    Abstract

    The role of gender in the development, treatment and prognosis of thoracic malignancies has been underappreciated and understudied. While most research has been grounded in tobacco-related malignancies, the incidence of non-smoking related lung cancer is on the rise and disproportionately affecting women. Recent research studies have unveiled critical differences between men and women with regard to risk factors, timeliness of diagnosis, incongruent screening practices, molecular and genetic mechanisms, as well as response to treatment and survival. These studies also highlight the increasingly recognized need for targeted therapies that account for variations in the response and complications as a function of gender. Similarly, screening recommendations continue to evolve as the role of gender is starting to be ellucidated. As women have been underrepresented in clinical trials until recently, the data regarding optimal care and outcomes is still lagging behind. Understanding the underlying similarities and differences between men and women is paramount to providing adequate care and prognostication to patients of either gender. This review provides an overview of the critical role that gender plays in the care of patients with non-small cell lung cancer and other thoracic malignancies, with an emphasis on the need for increased awareness and further research to continue elucidating these disparities.

    View details for DOI 10.21037/jtd-20-3128

    View details for PubMedID 34277072

    View details for PubMedCentralID PMC8264700

  • Impact of the Surgical Approach to Thymectomy Upon Complete Stable Remission Rates in Myasthenia Gravis: A Meta-analysis. Neurology Solis-Pazmino, P., Baiu, I., Lincango-Naranjo, E., Trope, W., Prokop, L., Ponce, O. J., Shrager, J. B. 2021

    Abstract

    OBJECTIVES: To determine whether the available operative techniques for thymectomy in myasthenia gravis (MG) confer variable chances for achieving complete stable remission (CSR), we performed a meta-analysis of comparative studies of surgical approaches to thymectomy.METHODS: Meta-analysis of all studies providing comparative data on thymectomy approaches, with CSR reported and minimum 3 years mean follow-up.RESULTS: 12 cohort studies and one randomized clinical trial, containing 1598 patients, met entry criteria. At 3 years, CSR from MG was similar following VATS extended vs. both basic (RR 1.00, p=1.00, 95% CI 0.39-2.58) and extended (RR 0.96, p=0.74, CI: 0.72-1.27) transsternal approaches. CSR at 3 years was also similar following extended transsternal vs. combined transcervical-subxiphoid (RR 1.08, p=0.62, CI: 0.8-1.44) approaches. VATS extended approaches remained statistically equivalent to extended transsternal approaches through 9 years of follow-up (RR 1.51, p=0.05, CI: 0.99-2.30). The only significant difference in CSR rate between a traditional open and a minimally invasive approach was seen at 10 years when comparing the now-abandoned basic (non-sternum-lifting) transcervical approach and the extended transsternal approach (RR 0.4, p=0.01, CI: 0.2-0.8).CONCLUSIONS: A significant difference in the rate of CSR among various surgical approaches for thymectomy in MG was identified only at long-term follow-up, and only between what might be considered the most aggressive approach (extended transsternal thymectomy) and the least aggressive approach (basic transcervical thymectomy). Extended minimally invasive approaches appear to have equivalent CSR rates to extended transsternal approaches and are therefore appropriate in the hands of experienced surgeons.

    View details for DOI 10.1212/WNL.0000000000012153

    View details for PubMedID 33947783

  • Impact of policy-based and institutional interventions on postoperative opioid prescribing practices. American journal of surgery Titan, A., Doyle, A., Pfaff, K., Baiu, I., Lee, A., Graham, L., Shelton, A., Hawn, M. 2021

    Abstract

    BACKGROUND: We assessed the impact of policy-based and institutional interventions to limit postoperative opioid prescribing.METHODS: Retrospective cohort study of patients who underwent laparoscopic/open appendectomies, laparoscopic/open cholecystectomies, and laparoscopic/open inguinal hernia repair during a 6-month interval in 2018 (control), 2019 (post-policy intervention), and 2020 (post-institutional intervention) to assess changes in postoperative opioid prescribing patterns. A survey was collected for the 2020 cohort.RESULTS: Comparing the 762 patients identified in 2018, 2019, and 2020 cohorts there was a significant decrease in mean opioid tabs prescribed (23.5±8.9 vs. 16.2±7.0 vs. 12.8±4.9, p<0.01) and mean OME dosage (148.0±68.0 vs. 108.6±51.8 vs. 95.4±38.0, p<0.01), without a difference in refill requests. Patient survey (response rate 63%) indicated 91.4% of patients reported sufficient pain control.CONCLUSION: Formalized opioid-prescribing guidelines and statewide regulations can significantly decrease postoperative opioid prescribing with good patient satisfaction. Surgeon education may facilitate efforts to minimize narcotic over-prescription without compromising pain management.

    View details for DOI 10.1016/j.amjsurg.2021.02.004

    View details for PubMedID 33593614

  • Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries LANCET Knight, S. R., Shaw, C. A., Pius, R., Drake, T. M., Norman, L., Ademuyiwa, A. O., Adisa, A. O., Aguilera-Arevalo, M., Al-Saqqa, S. W., Al-Slaibi, I. S., Bhangu, A., Biccard, B. M., Brocklehurst, P., Costas-Chavarri, A., Chu, K. M., Dare, A. J., Elhadi, M., Fairfield, C. J., Fitzgerald, J., Ghosh, D. N., Glasbey, J., Henegouwen, M., Ingabire, J., Kingham, T., Lapitan, M. M., Lawani, I., Lieske, B., Lilford, R. J., Martin, J., Mclean, K. A., Moore, R. L., Morton, D., Nepogodiev, D., Ntirenganya, F., Pata, F., Pinkney, T. D., Qureshi, A. U., Ramos-De la Medina, A., Riad, A. M., Salem, H., Simoes, J., Spence, R. T., Smart, N. J., Tabiri, S., Thomas, H. S., Weiser, T. G., West, M. A., Whitaker, J., Harrison, E. M., GlobalSurg Collaborative, Global Surg Writing Grp 2021; 397 (10272): 387–97

    Abstract

    80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications on postoperative mortality.This was a multicentre, international prospective cohort study of consecutive adult patients undergoing surgery for primary breast, colorectal, or gastric cancer requiring a skin incision done under general or neuraxial anaesthesia. The primary outcome was death or major complication within 30 days of surgery. Multilevel logistic regression determined relationships within three-level nested models of patients within hospitals and countries. Hospital-level infrastructure effects were explored with three-way mediation analyses. This study was registered with ClinicalTrials.gov, NCT03471494.Between April 1, 2018, and Jan 31, 2019, we enrolled 15 958 patients from 428 hospitals in 82 countries (high income 9106 patients, 31 countries; upper-middle income 2721 patients, 23 countries; or lower-middle income 4131 patients, 28 countries). Patients in LMICs presented with more advanced disease compared with patients in high-income countries. 30-day mortality was higher for gastric cancer in low-income or lower-middle-income countries (adjusted odds ratio 3·72, 95% CI 1·70-8·16) and for colorectal cancer in low-income or lower-middle-income countries (4·59, 2·39-8·80) and upper-middle-income countries (2·06, 1·11-3·83). No difference in 30-day mortality was seen in breast cancer. The proportion of patients who died after a major complication was greatest in low-income or lower-middle-income countries (6·15, 3·26-11·59) and upper-middle-income countries (3·89, 2·08-7·29). Postoperative death after complications was partly explained by patient factors (60%) and partly by hospital or country (40%). The absence of consistently available postoperative care facilities was associated with seven to 10 more deaths per 100 major complications in LMICs. Cancer stage alone explained little of the early variation in mortality or postoperative complications.Higher levels of mortality after cancer surgery in LMICs was not fully explained by later presentation of disease. The capacity to rescue patients from surgical complications is a tangible opportunity for meaningful intervention. Early death after cancer surgery might be reduced by policies focusing on strengthening perioperative care systems to detect and intervene in common complications.National Institute for Health Research Global Health Research Unit.

    View details for DOI 10.1016/S0140-6736(21)00001-5

    View details for Web of Science ID 000614227700026

    View details for PubMedID 33485461

    View details for PubMedCentralID PMC7846817

  • Author Spotlight: Ioana Baiu. Digestive diseases and sciences Baiu, I. 2021

    View details for DOI 10.1007/s10620-020-06811-4

    View details for PubMedID 33492531

  • Cec and You Shall Find: Cecal Perforation in a Patient with COVID-19. Digestive diseases and sciences Baiu, I., Forgo, E., Kin, C., Weiser, T. G. 2021

    View details for DOI 10.1007/s10620-020-06810-5

    View details for PubMedID 33492532

  • Carotid Artery Stenting. JAMA Baiu, I., Stern, J. R. 2020; 324 (16): 1690

    View details for DOI 10.1001/jama.2020.10426

    View details for PubMedID 33107946

  • Esophageal Cancer Surgery. JAMA Baiu, I., Backhus, L. 2020; 324 (15): 1580

    View details for DOI 10.1001/jama.2020.2101

    View details for PubMedID 33079155

  • Carotid Artery Endarterectomy. JAMA Baiu, I., Stern, J. R. 2020; 324 (1): 110

    View details for DOI 10.1001/jama.2020.2104

    View details for PubMedID 32633802

  • Periorbital and Orbital Cellulitis. JAMA Baiu, I., Melendez, E. 2020; 323 (2): 196

    View details for DOI 10.1001/jama.2019.18211

    View details for PubMedID 31935029

  • Understanding Health Care Utilization and Mortality After Emergency General Surgery in Patients With Underlying Liver Disease. The American surgeon Tennakoon, L. n., Baiu, I. n., Concepcion, W. n., Melcher, M. L., Spain, D. A., Knowlton, L. M. 2020; 86 (6): 665–74

    Abstract

    Mortality and complications are not well defined nationally for emergency general surgery (EGS) patients presenting with underlying all-cause liver disease (LD).We analyzed the 2012-2014 National Inpatient Sample for adults (aged ≥ 18 years) with a primary EGS diagnosis. Underlying LD included International Classification of Diseases, Ninth Revision, Clinical Modification codes for alcoholic and viral hepatitis, malignancy, congenital etiologies, and cirrhosis. The primary outcome was mortality; secondary outcomes included complications, operative intervention, and costs.Of the 6.8 million EGS patients, 358 766 (5.3%) had underlying LD. 59.1% had cirrhosis, 6.7% had portal hypertension, and 13.7% had ascites. Compared with other EGS patients, EGS-LD patients had higher mean costs ($12 847 vs $10 234, P < .001). EGS-LD patients were less likely to have surgery (26.1% vs 37.0%, P < .001) but for those who did, mortality was higher (4.8% vs 1.8%, P < .001). Risk factors for mortality included ascites (adjusted odds ratio [aOR] = 2.68, P < .001), dialysis (aOR = 3.44, P < .001), sepsis (aOR = 8.97, P < .001), and respiratory failure requiring intubation (aOR = 10.40, P < .001). Odds of death increased in both surgical (aOR = 4.93, P < .001) and non-surgical EGS-LD patients (aOR = 2.56, P < .001).Underlying all-cause LD among EGS patients is associated with increased in-hospital mortality, even in the absence of surgical intervention.

    View details for DOI 10.1177/0003134820923304

    View details for PubMedID 32683972

  • The Cava. Trauma surgery & acute care open Baiu, I. 2020; 5 (1): e000480

    View details for DOI 10.1136/tsaco-2020-000480

    View details for PubMedID 32377570

  • A National Analysis of Minimally Invasive vs Open Segmentectomy for Stage IA Non-small-cell Lung Cancer. Seminars in thoracic and cardiovascular surgery Kumar, A. n., Deng, J. n., Raman, V. n., Okusanya, O. n., Baiu, I. n., Berry, M. F., D'Amico, T. A., Yang, C. J. 2020

    Abstract

    The objective of this study was to compare long-term outcomes of open versus minimally invasive (MIS) segmentectomy for early stage non-small-cell lung cancer (NSCLC), which has not been evaluated using national studies. Outcomes of open versus MIS segmentectomy for clinical T1, N0, M0 NSCLC in the National Cancer Data Base (2010-2015) were evaluated using propensity score matching. Of the 39,351 patients who underwent surgery for stage IA NSCLC from 2010-2015, 770 underwent segmentectomy by thoracotomy and 1,056 by MIS approach (876 thoracoscopic [VATS], 180 robotic). The MIS to open conversion rate was 6.7% (n=71).  After propensity-score matching, all baseline characteristics were well-balanced between the open (n=683) and MIS (n=683) groups. When compared to the open group, the MIS group had shorter median length of stay (LOS) (4 vs 5 days, p<0.001) and lower 30-day mortality (0.6% vs 1.9%, p=0.037). There were no significant differences between MIS and open groups with regard to 30-day readmission (5.0% vs 3.7%, p=0.43), or upstaging from cN0 to pN1/N2/N3 (3.1% vs 3.6%, p=0.89). The MIS approach was associated with similar long-term overall survival as the open approach (5-year survival: 62.3% vs 63.5%, p=0.89; multivariable-adjusted HR: 0.99, 95% CI: 0.82-1.21, p=0.96). In this national analysis of open versus MIS segmentectomy for clinical stage IA NSCLC, MIS was associated with shorter LOS and lower perioperative mortality, and similar nodal upstaging and 5-year survival when compared to segmentectomy via thoracotomy. MIS segmentectomy does not appear to compromise oncologic outcomes for clinical stage IA NSCLC.

    View details for DOI 10.1053/j.semtcvs.2020.09.009

    View details for PubMedID 32977013

  • The Trauma Scene. JAMA Baiu, I., Knowlton, L. M. 2020; 324 (4): 406

    View details for DOI 10.1001/jama.2020.2580

    View details for PubMedID 32721010

  • Paraesophageal Hernia Repair and Fundoplication. JAMA Baiu, I., Lau, J. 2019; 322 (24): 2450

    View details for DOI 10.1001/jama.2019.17390

    View details for PubMedID 31860048

  • What Is a Paraesophageal Hernia? JAMA Baiu, I., Lau, J. 2019; 322 (21): 2146

    View details for DOI 10.1001/jama.2019.17395

    View details for PubMedID 31794626

  • What Is a Tracheostomy? JAMA Baiu, I., Backhus, L. 2019; 322 (19): 1932

    View details for DOI 10.1001/jama.2019.14994

    View details for PubMedID 31742632

  • Enteral Nutrition. JAMA Baiu, I., Spain, D. A. 2019; 321 (20): 2040

    View details for DOI 10.1001/jama.2019.4407

    View details for PubMedID 31135851

  • Rib Fractures. JAMA Baiu, I., Spain, D. 2019; 321 (18): 1836

    View details for PubMedID 31087024

  • Croup. JAMA Baiu, I., Melendez, E. 2019; 321 (16): 1642

    View details for DOI 10.1001/jama.2019.2013

    View details for PubMedID 31012936

  • Minimally Invasive Small Bowel Cancer Surgery. Surgical oncology clinics of North America Baiu, I., Visser, B. C. 2019; 28 (2): 273–83

    Abstract

    Small bowel malignancies are extremely rare. Surgical resection is often the mainstay of treatment with the extent of the operation depending on the type of tumor. Whereas neuroendocrine tumors and adenocarcinoma require lymph node resection, gastrointestinal stromal tumors do not typically metastasize to regional nodes and therefore need resection only. Minimally invasive approaches are applicable to small tumors that require a limited resection and reconstruction and have been shown to have equal survival benefits with decreased risk of postoperative complications.

    View details for PubMedID 30851828

  • Minimally Invasive Small Bowel Cancer Surgery SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA Baiu, I., Visser, B. C. 2019; 28 (2): 273-+
  • Parenteral Nutrition. JAMA Baiu, I. n., Spain, D. A. 2019; 321 (21): 2142

    View details for DOI 10.1001/jama.2019.4410

    View details for PubMedID 31162570

  • Epiglottitis. JAMA Baiu, I., Melendez, E. 2019; 321 (19): 1946

    View details for DOI 10.1001/jama.2019.3468

    View details for PubMedID 31112260

  • Sigmoid Volvulus. JAMA Baiu, I., Shelton, A. 2019; 321 (24): 2478

    View details for DOI 10.1001/jama.2019.2349

    View details for PubMedID 31237646

  • Mucormycosis emboli: a rare cause of segmental bowel ischemia. Trauma surgery & acute care open Baiu, I., Knowlton, L. M. 2019; 4 (1): e000305

    View details for DOI 10.1136/tsaco-2019-000305

    View details for PubMedID 31245621

  • Acute severe iatrogenic hyponatremia. Trauma surgery & acute care open Baiu, I., Kang, M., Weiser, T. G. 2019; 4 (1): e000388

    View details for DOI 10.1136/tsaco-2019-000388

    View details for PubMedID 31750400

  • Necrotizing Soft Tissue Infections. JAMA Baiu, I. n., Staudenmayer, K. n. 2019; 321 (17): 1738

    View details for PubMedID 31063576

  • Rhinovirus-associated severe acute respiratory distress syndrome (ARDS) managed with airway pressure release ventilation (APRV). Trauma surgery & acute care open Ayala, C. n., Baiu, I. n., Owyang, C. n., Forrester, J. D., Spain, D. n. 2019; 4 (1): e000322

    View details for DOI 10.1136/tsaco-2019-000322

    View details for PubMedID 31392279

    View details for PubMedCentralID PMC6660799

  • Talc Pleurodesis: a Medical, Medicolegal, and Socioeconomic Review. The Annals of thoracic surgery Baiu, I. n., Yevudza, E. n., Shrager, J. B. 2019

    Abstract

    Talcum has been used in pleurodesis for over eight decades. Despite a wealth of research, controversy remains over the optimal sclerosant for pneumothorax and pleural effusions. Talc's historical primacy has been challenged due to its potential for pulmonary toxicity, possible carcinogenicity, and recent concerns surrounding availability and legal liability, making an ideal time for a review.This is a systematic review of the talc literature, focused on publications after the year 2000 evaluating mechanism of action, efficacy, side-effect profile, and alternative sclerosants; included is an overview of current socioeconomic and legal controversies.The data support talc as the most effective agent for pleurodesis. There is evidence to suggest that mean particle size has a direct relationship to the side-effect profile and that significant hypoxemic events following talc administration are exceedingly rare using available graded talc preparations. Concerns regarding the development of malignancies following topical talc application remain incompletely resolved but appear related to cosmetic powder preparations that were contaminated with asbestos. Purified talc in the pleural space has not been implicated. Recent difficulties accessing commercial talc preparations have been solved. Although safe and effective talc alternatives do exist, these agents are not as well studied.Talc pleurodesis with modern, purified, graded talc preparations is safe and highly effective. Talc is an inexpensive and accessible option that remains appropriate for pleurodesis despite existing controversies.

    View details for DOI 10.1016/j.athoracsur.2019.08.104

    View details for PubMedID 31593652

  • Caring for Caregivers - Resident Physician Health and Wellbeing. Journal of surgical education Baiu, I. n., Titan, A. n., Kin, C. n., Spain, D. A. 2019

    Abstract

    There is a national epidemic of physician burnout and serious concerns exist regarding the well-being of future physicians. This project seeks to address resident physician health, by creating a sense of support and community during training, as a method to target one of the many facets of burnout.We created a program that allows residents who fall ill to receive a health package, delivered to work or home, consisting of essential medications, vitamins, nutrition, and hydration. The recipients were asked to answer a short survey regarding their experience.Stanford Health Care, Department of Surgery, Division of General Surgery, Palo Alto California.Eighteen packages have been delivered since the start of the project. One hundred percent of residents agree that this program fulfills an otherwise unmet need in residency. Similarly, all felt that the supplies they received helped them recover faster. The majority (83%) of the packages were requested by colleagues of the ill residents.We present an innovative project aimed at improving resident physician health, fostering a feeling of support, and helping to reduce resident burnout. This is the first report of a program of this kind and we hope that it incentivizes a broader discussion and implementation of similar initiatives in other residency programs across the country.

    View details for DOI 10.1016/j.jsurg.2019.08.007

    View details for PubMedID 31494061

  • When Lightning Strikes Twice DIGESTIVE DISEASES AND SCIENCES Baiu, I., Charville, G. W., Visser, B. C. 2018; 63 (10): 2536–40
  • Small Bowel Obstruction. JAMA Baiu, I., Hawn, M. T. 2018; 319 (20): 2146

    View details for DOI 10.1001/jama.2018.5834

    View details for PubMedID 29800183

  • Skin Abscess. JAMA Baiu, I., Melendez, E. 2018; 319 (13): 1405

    View details for DOI 10.1001/jama.2018.1355

    View details for PubMedID 29614180

  • Anaphylaxis in Children. JAMA Baiu, I., Melendez, E. 2018; 319 (9): 943

    View details for DOI 10.1001/jama.2018.0447

    View details for PubMedID 29509868

  • Nursemaid's Elbow (Elbow Subluxation). JAMA Baiu, I., Melendez, E. 2018; 319 (5): 515

    View details for DOI 10.1001/jama.2017.22031

    View details for PubMedID 29411033

  • When Lightning Strikes Twice. Digestive diseases and sciences Baiu, I. n., Charville, G. W., Visser, B. C. 2018

    View details for PubMedID 29302877